[go: up one dir, main page]

DE69233398D1 - Modifizierter faktor-vii - Google Patents

Modifizierter faktor-vii

Info

Publication number
DE69233398D1
DE69233398D1 DE69233398T DE69233398T DE69233398D1 DE 69233398 D1 DE69233398 D1 DE 69233398D1 DE 69233398 T DE69233398 T DE 69233398T DE 69233398 T DE69233398 T DE 69233398T DE 69233398 D1 DE69233398 D1 DE 69233398D1
Authority
DE
Germany
Prior art keywords
factor vii
modified
modified factor
treat
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69233398T
Other languages
English (en)
Inventor
L Berkner
Christian Petersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk Health Care AG
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, Zymogenetics Inc filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE69233398D1 publication Critical patent/DE69233398D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69233398T 1991-02-28 1992-02-28 Modifizierter faktor-vii Expired - Lifetime DE69233398D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66292091A 1991-02-28 1991-02-28
PCT/US1992/001636 WO1992015686A1 (en) 1991-02-28 1992-02-28 Modified factor vii

Publications (1)

Publication Number Publication Date
DE69233398D1 true DE69233398D1 (de) 2004-09-16

Family

ID=24659758

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69233398T Expired - Lifetime DE69233398D1 (de) 1991-02-28 1992-02-28 Modifizierter faktor-vii

Country Status (8)

Country Link
EP (2) EP0575464B1 (de)
JP (2) JP3459416B2 (de)
AT (1) ATE273393T1 (de)
AU (1) AU672357B2 (de)
CA (1) CA2103546C (de)
DE (1) DE69233398D1 (de)
HU (1) HU218890B (de)
WO (1) WO1992015686A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
AU703110B2 (en) * 1993-05-21 1999-03-18 Novo Nordisk A/S Modified factor VII
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
AU8101698A (en) 1997-07-18 1999-02-10 Novo Nordisk A/S Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
EP1163268B1 (de) 1999-03-15 2011-05-11 Novo Nordisk A/S Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
AU5247400A (en) * 1999-06-14 2001-01-02 Chisso Corporation Substance binding to the substrate of activated blood coagulation factor in competition with this factorto thereby regulate the r eaction between the activated blood coagulation factor and the substrate, a process for producing the substance and blood coagulation
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US8202973B2 (en) * 2000-10-02 2012-06-19 Novo Nordisk Health Care Ag Method for the production of vitamin K-dependent proteins
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
HUP0401124A3 (en) 2001-03-22 2006-01-30 Novo Nordisk Healthcare Ag Coagulation factor vii derivatives
WO2002087605A2 (en) * 2001-05-02 2002-11-07 Novo Nordisk A/S Modified fvii in treatment of ards
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
ATE428439T1 (de) 2001-12-21 2009-05-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
JP2005523723A (ja) 2002-04-30 2005-08-11 マキシゲン ホルディングス リミテッド 第ＶＩＩ因子または第ＶＩＩａ因子のポリペプチド変種
ATE536886T1 (de) * 2002-05-03 2011-12-15 Novo Nordisk As Stabilisierte feste zusammensetzungen von modifizierter faktor vii
HUE037603T2 (hu) 2002-06-21 2018-09-28 Novo Nordisk Healthcare Ag VIIa faktor polipeptideket tartalmazó stabilizált, szilárd készítmények
EP2085470B1 (de) 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII oder FVIIa Varianten
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
EP1628677B1 (de) 2003-05-23 2010-01-13 Novo Nordisk Health Care AG Stabilisierung von proteinen in lösung
DE602004025576D1 (de) 2003-06-19 2010-04-01 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
MXPA06001698A (es) 2003-08-14 2006-05-19 Novo Nordisk Healthcare Ag Composicion farmaceutica liquida y acuosa de polipetidos de factor vii.
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
BRPI0416950B8 (pt) 2003-12-01 2021-05-25 Novo Nordisk Healthcare Ag métodos para remover vírus de uma composição do fator vii líquida, para inativar vírus em uma composição do fator vii líquida, e para eliminar em alto nível a presença de vírus ativos em uma composição do fator vii líquida.
EP1703899B1 (de) 2003-12-19 2011-05-04 Novo Nordisk Health Care AG Stabilisierte zusammensetzungen von faktor-vii-polypeptiden
EP2586456B1 (de) 2004-10-29 2016-01-20 ratiopharm GmbH Umformung und GlycoPEGylierung des Fibroblastenwachstumsfaktors (FGF)
AU2006203792B2 (en) 2005-01-10 2011-11-03 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
EP1924689B1 (de) 2005-09-01 2014-08-13 Novo Nordisk Health Care AG Reinigung von faktor-vii-polypeptiden mittels hydrophober interaktionschromatografie
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
PT2574677T (pt) 2007-12-27 2017-10-19 Baxalta Inc Processos para cultura de células
AU2009219232B2 (en) 2008-02-27 2014-02-27 Novo Nordisk A/S Conjugated Factor VIII molecules
AR077041A1 (es) 2009-06-09 2011-07-27 Prolong Pharmaceuticals Inc Composiciones de hemoglobina. metodos.
WO2014060397A1 (en) 2012-10-15 2014-04-24 Novo Nordisk Health Care Ag Factor vii conjugates
WO2017121436A1 (en) 2016-01-15 2017-07-20 Rigshospitalet Quantitative pet imaging of tissue factor expression using 18f-labled active site inhibited factor vii
MA46864A (fr) 2016-11-17 2021-04-28 Minerva Imaging Aps Facteur vii inhibé par le site actif marqué par 177-lu

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69131292T2 (de) * 1990-01-29 1999-09-30 Zymogenetics, Inc. Antikoagulierende proteine

Also Published As

Publication number Publication date
HUT71572A (en) 1995-12-28
JP2003289890A (ja) 2003-10-14
ATE273393T1 (de) 2004-08-15
JPH06504678A (ja) 1994-06-02
EP0575464B1 (de) 2004-08-11
WO1992015686A1 (en) 1992-09-17
AU1449892A (en) 1992-10-06
HU218890B (hu) 2000-12-28
AU672357B2 (en) 1996-10-03
EP1479395A1 (de) 2004-11-24
EP0575464A1 (de) 1993-12-29
JP3459416B2 (ja) 2003-10-20
CA2103546A1 (en) 1992-08-29
CA2103546C (en) 2002-10-01
HU9302438D0 (en) 1993-12-28

Similar Documents

Publication Publication Date Title
ATE273393T1 (de) Modifizierter faktor-vii
DK0699075T3 (da) Modificeret faktor VII
MX9702951A (es) Factor vii modificado.
DK0674513T3 (da) Retroviral protease-inhiberende forbindelser
BR9709661A (pt) Processos para inibir a formação de trombos em um paciente, para manter ou melhorar a patência vascular em um paciente, para evitar ou minimizar o dano miocardìaco associado com reperfusão pós-isquêmica em um indivìduo, e, para melhorar o fluxo sanguìneo no miocárdio regional durante a reperfusão pós-isquêmica em um indivìduo, e, uso do fator vii
DE69304955D1 (de) Behandlung von neurodegenerativen Erkrankungen
ATE175876T1 (de) Verkürzter gewebsfaktor und fviia oder fvii zur aktivierung der blutgerinnung
ATE101524T1 (de) Hirudin und aktivator des plasminogens enthaltende pharmazeutische wirksame verbindung.
SE8704298D0 (sv) Compounds for use in therapy
MX9203032A (es) Una solucion farmaceutica.
DK1030836T3 (da) Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
NO864443L (no) Fremgangsmaate for fremstilling av terapeutisk aktive n-substituerte 3-piperidin- eller 3-pyridin-karboksylsyrederivater.
ES2068216T3 (es) Compuestos de tienotriazolodiazepina y usos farmaceuticos de los mismos.
ATE141605T1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen
BE1002239A5 (fr) Solution pharmaceutique.
DE69303234D1 (de) Behandlung von entzündlichen Darmerkrankungen
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
DE69201066D1 (de) Colominsäure und Produkte einer teilweisen Hydrolyse von Colominsäure zur Herstellung von Arzneimitteln zur Behandlung von Hepatitis, Nephritis und Arthritis.
DK0589741T3 (da) Anvendelse af en direkte thrombininhibitor til fremstilling af et lægemiddel med thrombolytisk aktivitet
DK0437025T3 (da) Midler indeholdende aldosereduktaseinhibitorer til behandling af ulcera
FI883730A0 (fi) Etrar och tioetrar med terapeutisk effekt, framstaellning av dessa och farmaceutiska sammansaettningar som innehaoller dem.
ATE353666T1 (de) Verwendung von aktiviertem gerinnungsfaktor vii zur behandlung von durch thrombolytische therapie-induzierten wichtigen blutungen
DE69932434D1 (de) Prophylaxe und Behandlung von autoimmunen Entmyelinisierungserkrankungen durch Fas-antagonisten
DK0673646T3 (da) Anvendelse af deoxyspergualin til fremstilling af et lægemiddel til behandling af inflammatorisk-hyperreaktive sygdomme

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: NOVO NORDISK HEALTH CARE AG, ZUERICH, CH

Owner name: NOVO NORDISK A/S, BAGSVAERD, DK

8332 No legal effect for de